SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC

• Status: Completed
• Trial end date: 2019-04-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the resectability after treatment with SECOX (sorafenib, capecitabine, oxaliplatin) as neoadjuvant therapy in patients with locally advanced hepatocellular carcinoma

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Hong Kong
• Treatments: Capecitabine; Oxaliplatin; Sorafenib

Criteria

Inclusion Criteria:

• HCC confined to single lobe of non-cirrhotic liver (locally advanced) and not suitable for surgery or loco-regional therapies at the time of study entry, but can become resectable after treatment

• Diagnosis of HCC confirmed by histology

• Child-Pugh class A cirrhosis with adequate remnant liver parenchyma

• Measurable disease

• Fit enough to undergo surgery to resect the primary liver tumour

Exclusion Criteria:

• Prior systemic therapy for HCC

• Presence of extrahepatic metastasis

• History of liver transplantation

• Peripheral sensory neuropathy with functional impairment

• Uncontrolled hypertension/ cardiac disease